Hemostasis diagnostic devices market seen growing to $10.12 billion by 2030

The global market for hemostasis diagnostic devices and equipment is forecast to climb from $5.66 billion in 2025 to $6.42 billion in 2026, with further growth to $10.12 billion by 2030. Rising surgical procedures, bleeding disorders and demand for faster clotting tests are driving adoption across hospitals and laboratories.

Why it matters: - Hemostasis testing helps clinicians track blood clotting and manage bleeding disorders during surgery and routine care. - Faster and more accurate coagulation diagnostics can reduce surgical complications and support better patient management. - The market is expanding as hospitals and labs face more demand for rapid, point-of-care testing and advanced analysis tools.

What happened: - The hemostasis diagnostic devices and equipment market is projected to rise from $5.66 billion in 2025 to $6.42 billion in 2026. - That 2025-2026 increase reflects a 13.4% compound annual growth rate. - The market is expected to reach $10.12 billion by 2030, growing at a 12.0% CAGR over the forecast period. - The Business Research Company released the report on August 10, 2026. - Download a free sample of the report. - View the full market report.

The details: - Hemostasis diagnostic devices and equipment are specialized instruments used to evaluate blood clotting and detect bleeding disorders. - These tools help healthcare providers monitor clot formation and breakdown. - The report links near-term growth to higher rates of bleeding disorders, more surgical procedures, wider hospital laboratory services and broader use of standardized clotting tests. - Advanced coagulation reagents also support the market's expansion. - Longer-term growth is tied to demand for rapid bedside diagnostic tools, AI-assisted coagulation analysis, personalized anticoagulant therapies, advanced laboratory infrastructure and preventive diagnostics. - Key trends include broader use of automated coagulation analyzers, more point-of-care hemostasis testing, digital tools for interpreting results, comprehensive clotting analysis systems and faster diagnostic turnaround times. - North America held the largest share of the global market in 2025. - Asia-Pacific was the second-largest regional market. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market's growth points to a broader shift toward earlier, faster and more data-driven clotting diagnostics. - AI-assisted analysis and digital interpretation suggest laboratory workflows are becoming more automated and less dependent on manual review. - The focus on point-of-care testing signals stronger demand for decisions made closer to the patient, especially in surgical settings. - A BBC report in April 2025 said around 27,462 cosmetic surgical procedures were performed in the UK in 2024, up 5% from 2023, with more than 90% performed on women.

What's next: - The report expects continued expansion through 2030 as preventive diagnostics and personalized anticoagulant care gain ground. - The company said 2026 report updates include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The company also listed contact details for expert follow-up and sales inquiries.

The bottom line: - Hemostasis diagnostics are moving from a specialized lab niche toward a faster, more automated and more widely used part of surgical and bleeding-disorder care.